Potential of Concentration Monitoring Data for a Short Half‐Life Drug: Analysis of Pharmacokinetic Variability for Moclobemide

  title={Potential of Concentration Monitoring Data for a Short Half‐Life Drug: Analysis of Pharmacokinetic Variability for Moclobemide},
  author={M. Gex-fabry and Androniki E. Balant-Gorgia and Luc P. Balant},
  journal={Therapeutic Drug Monitoring},
The pharmacokinetic variability of moclobemide, a new short half-life reversible selective inhibitor of monoamine oxidase (MAO) was investigated through analysis of concentrations measured during early open clinical use. Eighty-nine depressed patients, aged 21–96 years, were included in the present study. Doses ranged from 200 to 900 mg/day, and the time interval between blood sampling and last drug intake on the previous day was between 8 and 23 h. Intraindividual variability was generally… Expand
Evaluation of Single‐Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients
As the most reliable surrogate for moclobemide systemic exposure, concentrations at 4 and 6 hours should be used instead of predose trough concentrations as an indicator of between‐patient variability and a guide for dose adjustments in specific clinical situations. Expand
Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.
Therapeutic drug monitoring data, collected in patients representative of the population for which the drug was intended, allowed us to quantify the dose reduction needed in elderly patients and thus provided valuable information in addition to the one collected during premarketing studies performed with strict inclusion and exclusion criteria. Expand
Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting.
The results highlight sertraline TDM as a tool for individual dose optimization and evaluation of patient drug compliance as well as drug-drug interactions. Expand
Quetiapine Serum Concentrations in Psychiatric Patients: The Influence of Comedication
Steady-state serum concentrations of quetiapine were recorded in 62 psychiatric patients under routine conditions and may serve as an orienting interval for serum concentrations observed under routine treatment conditions. Expand
Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication.
Analysis of the ratios of dose-normalized exposed to nonexposed concentrations indicated that phenothiazine comedication led to significantly higher concentrations of desmethylated metabolites but not parent compounds, when clomipramine, imipramines, or amitriptyline were administered. Expand
Death following acute poisoning by moclobemide.
It was concluded that the manner ofdeath was suicide and that the unique cause of death was massive ingestion of moclobemide, and the other xenobiotics were considered of little toxicological relevance. Expand
Therapeutic Drug Monitoring
Patients treated with psychotropic medications for which therapeutic drug monitoring (TDM) was found useful include poor compliance, patients who are ultra-rapid or poor metabolisers, elderly patients, instances of metabolic inhibition and induction, and patients with liver dysfunction. Expand
Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study
Abstract A SPE-HPLC-UV method for determination of moclobemide and its major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma had been developed previously and its selectivity was evaluatedExpand
Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions
Among factors to consider for improved effectiveness in the use of TDM databases for postmarketing surveillance of drug-drug interactions, integration of efficacy and safety data in future studies and communication of expert recommendations to prescribing physicians are essential. Expand
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical,Expand